Home
Camilla Krakstad's picture

Camilla Krakstad

Professor
  • E-mailCamilla.Krakstad@uib.no
  • Phone+47 55 97 67 97+47 992 54 140
  • Visitor Address
    Kvinneklinikken Haukeland University Hospital
    Department of Clinical Science
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) 2021. Nuclear upregulation of class I phosphoinositide 3-kinase p110β correlates with high 47S rRNA levels in cancer cells. Journal of Cell Science. 1-13.
  • Show author(s) 2021. Cancer awareness in the general population varies with sex, age and media coverage: A population-based survey with focus on gynecologic cancers. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 25-31.
  • Show author(s) 2021. Automated segmentation of endometrial cancer on MR images using deep learning. Scientific Reports.
  • Show author(s) 2020. Whole-volume tumor MRI radiomics for prognostic modeling in endometrial cancer. Journal of Magnetic Resonance Imaging. 1-10.
  • Show author(s) 2020. Tumour texture features from preoperative CT predict high-risk disease in endometrial cancer. Clinical Radiology. 1-8.
  • Show author(s) 2020. RadEx: Integrated visual exploration of multiparametric studies for radiomic tumor profiling. Computer Graphics Forum. 611-622.
  • Show author(s) 2020. Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Medicine.
  • Show author(s) 2020. Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. European Radiology. 2443-2453.
  • Show author(s) 2020. Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers. 1-18.
  • Show author(s) 2020. Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecologic Oncology. 1-9.
  • Show author(s) 2020. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
  • Show author(s) 2020. Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer. 1014-1022.
  • Show author(s) 2019. Poor outcome in hypoxic endometrial carcinoma is related to vascular density. British Journal of Cancer. 1037-1044.
  • Show author(s) 2019. Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. PLOS ONE. 1-13.
  • Show author(s) 2019. PIK3CA amplification associates with aggressive phenotype but not markers of AKT-mTOR signaling in endometrial carcinoma. Clinical Cancer Research. 334-345.
  • Show author(s) 2019. Impact of body mass index and fat distribution on sex steroid levels in endometrial carcinoma: A retrospective study. BMC Cancer. 1-8.
  • Show author(s) 2019. Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism.
  • Show author(s) 2019. Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Gynecologic Oncology. 400-406.
  • Show author(s) 2019. Blood metabolites associate with prognosis in endometrial cancer. Metabolites. 1-15.
  • Show author(s) 2019. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Human Pathology. 90-98.
  • Show author(s) 2018. rs495139 in the TYMS-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. International Journal of Molecular Sciences. 1-13.
  • Show author(s) 2018. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLOS ONE. 1-13.
  • Show author(s) 2018. Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer. Journal of Magnetic Resonance Imaging. 1637-1647.
  • Show author(s) 2018. Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiologica. 1010-1017.
  • Show author(s) 2018. L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition. Virchows Archiv. 591-598.
  • Show author(s) 2018. Identification of nine new susceptibility loci for endometrial cancer. Nature Communications. 1-12.
  • Show author(s) 2018. Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLOS ONE. 1-21.
  • Show author(s) 2018. Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Medicine. 1978-1987.
  • Show author(s) 2018. Development of an image-guided orthotopic xenograft mouse model of endometrial cancer with controllable estrogen exposure. International Journal of Molecular Sciences. 1-16.
  • Show author(s) 2018. Blood steroids are associated with prognosis and fat distribution in endometrial cancer. Gynecologic Oncology. 46-52.
  • Show author(s) 2018. Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach. Journal of Pathology. 203-214.
  • Show author(s) 2018. Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. BJOG: An International Journal of Obstetrics and Gynaecology. 1695-1703.
  • Show author(s) 2017. Type of vascular invasion in association with progress of endometrial cancer. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1084-1091.
  • Show author(s) 2017. Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients. OncoTarget. 109018-109026.
  • Show author(s) 2017. Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. OncoTarget. 106989-107001.
  • Show author(s) 2017. Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
  • Show author(s) 2017. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports. 1-12.
  • Show author(s) 2017. Increased microvascular permeability in mice lacking Epac1 (Rapgef3). Acta Physiologica. 441-452.
  • Show author(s) 2017. In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. Acta Radiologica. 497-505.
  • Show author(s) 2017. High visceral fat percentage is associated with poor outcome in endometrial cancer. OncoTarget. 105184-105195.
  • Show author(s) 2017. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • Show author(s) 2017. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecologic Oncology. 672-677.
  • Show author(s) 2017. Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. British Journal of Cancer. 840-847.
  • Show author(s) 2017. Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. OncoTarget. 3881-3894.
  • Show author(s) 2017. Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. American Journal of Obstetrics and Gynecology. 432.e1-432.e17.
  • Show author(s) 2017. Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. Gynecologic Oncology. 197-203.
  • Show author(s) 2016. Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. OncoTarget. 69844-69856.
  • Show author(s) 2016. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
  • Show author(s) 2016. High mRNA levels of 17β-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer. Molecular and Cellular Endocrinology. 51-57.
  • Show author(s) 2016. Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility.
  • Show author(s) 2016. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. OncoTarget. 69097-69110.
  • Show author(s) 2016. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • Show author(s) 2016. Androgen receptor as potential therapeutic target in metastatic endometrial cancer. OncoTarget. 49289-49298.
  • Show author(s) 2015. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Molecular Oncology. 1694-1703.
  • Show author(s) 2015. Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 1574-1584.
  • Show author(s) 2015. Multimodal imaging of orthotopic mouse model of endometrial carcinoma. PLOS ONE. 11 pages.
  • Show author(s) 2015. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • Show author(s) 2015. Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma. Gynecologic Oncology. 529-537.
  • Show author(s) 2015. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics. 164-171.
  • Show author(s) 2015. Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics. 888-897.
  • Show author(s) 2015. Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology. 542-548.
  • Show author(s) 2015. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology. 689-697.
  • Show author(s) 2015. Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLOS ONE.
  • Show author(s) 2015. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications.
  • Show author(s) 2015. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. International Journal of Cancer. 1863-1873.
  • Show author(s) 2015. ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
  • Show author(s) 2014. Switch in FOXA1 status associates with endometrial cancer progression. PLOS ONE.
  • Show author(s) 2014. Stathmin Protein Level, a Potential Peredictive Marker for Taxane Treatment Response in Endometrial Cancer. PLOS ONE.
  • Show author(s) 2014. Risk of ovarian cancer and the NF-kB pathway: Genetic association with IL1A and TNFSF10. Cancer Research. 852-861.
  • Show author(s) 2014. Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer.
  • Show author(s) 2014. Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. Pathology, Research and Practice. 774-778.
  • Show author(s) 2014. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. European Journal of Cancer. 3003-3010.
  • Show author(s) 2014. Landscape of genomic alterations in cervical carcinomas. Nature. 371-375.
  • Show author(s) 2014. Introduction of aromatic ring-containing substituents in cyclic nucleotides is associated with inhibition of toxin uptake by the hepatocyte transporters OATP 1B1 and 1B3. PLOS ONE.
  • Show author(s) 2014. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. OncoTarget. 1052-1061.
  • Show author(s) 2014. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
  • Show author(s) 2014. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • Show author(s) 2014. Consortium analysis of diet-gene interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition & Food Research. 2023-2035.
  • Show author(s) 2013. Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 216-223.
  • Show author(s) 2013. Off-target effect of the Epac agonist 8-pCPT-2'-O-Me-cAMP on P2Y12 receptors in blood platelets. Biochemical and Biophysical Research Communications - BBRC. 603-608.
  • Show author(s) 2013. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics. 371-384.
  • Show author(s) 2013. Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical Cancer Research. 1094-1105.
  • Show author(s) 2013. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLOS ONE. 9 pages.
  • Show author(s) 2013. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications. 12 pages.
  • Show author(s) 2013. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer. 3431-3441.
  • Show author(s) 2013. High phospho-stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clinical Cancer Research. 2331-2341.
  • Show author(s) 2013. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics. 362-370.
  • Show author(s) 2013. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications. 10 pages.
  • Show author(s) 2013. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Modern Pathology. 428-434.
  • Show author(s) 2012. Loss of GPER identifies new targets for therapy among a subgroup of ER alpha-positive endometrial cancer patients with poor outcome. British Journal of Cancer. 1682-1688.
  • Show author(s) 2012. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. British Journal of Cancer. 1997-2004.
  • Show author(s) 2012. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLOS ONE.
  • Show author(s) 2012. Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiology, Biomarkers and Prevention. 980-987.
  • Show author(s) 2011. Nostocyclopeptide-M1: A potent, nontoxic inhibitor of the hepatocyte drug transporters OATP1B3 and 1B1. Molecular Pharmaceutics. 360-367.
  • Show author(s) 2011. Cyclic AMP induces IPC leukemia cell apoptosis via CRE-and CDK-dependent Bim transcription. Cell Death and Differentiation. 11 pages.
  • Show author(s) 2009. Epac-induced Alterations in the Proteome of Human SH-SY5Y Neuroblastoma Cells. Journal of Proteomics & Bioinformatics. 244-245.
  • Show author(s) 2008. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
  • Show author(s) 2008. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 2866-2877.
  • Show author(s) 2006. CaM-kinasell-dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation. Cell Death and Differentiation. 1191-1202.
  • Show author(s) 2004. cAMP protects neutrophils against TNF?-induced apoptosis by activation of cAMP-dependent protein kinase, independently of exchange protein directly activated by cAMP (Epac). Journal of Leukocyte Biology. 641-647.
  • Show author(s) 2003. cAMP effector mechanisms. Novel twists for an "old" signaling system. FEBS Letters. 121-126.
  • Show author(s) 2003. Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells. Chemistry and Biology. 609-618.
  • Show author(s) 2002. Ca2+/calmodulin dependent protein kinase II is required for microcystin-induced apoptosis. Journal of Biological Chemistry. 2804-2811.
Academic lecture
  • Show author(s) 2004. cAMP protects neutrophils against TNFa-induced apoptosis by activation of cAMP-dependent protein kinase (cA-PK), independently of exchange protein directly activated by cAMP (Epac).
  • Show author(s) 2004. cAMP protects neutrophils against TNF_-induced apoptosis by activation of cAMP-dependent protein kinase (cA-PK), independently of exchange protein directly activated by cAMP (Epac).
  • Show author(s) 2004. Apoptotic phenotypes induced by natural toxins - Okadaic Acid acts by short-circuiting an ancient irradiation induced death pathway.
  • Show author(s) 2003. cAMP effector mechanisms. Novel twists for an "old" signalling system.
  • Show author(s) 2002. cAMP protects neutrophils against TNF_-induced apoptosis by activation of cAMP-dependent protein kinase (cA-PK), independently of exchange protein directly activated by cAMP (Epac).
  • Show author(s) 2001. Cell death in HeLa cells.
  • Show author(s) 1998. Distinct apoptotic death forms. Distinct pathways and functions?
Reader opinion piece
  • Show author(s) 2012. Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology. 516-519.
Masters thesis
  • Show author(s) 2008. Quantitative proteomics of Epac signaling in differentiating human SH-SY5Y neuroblastoma cells.
  • Show author(s) 2008. Epac-induced neuronal differentiation of Human SH-SY5Y neuroblastoma cells.
  • Show author(s) 2005. Role of Cu/Zn superoxide dismutase (SOD1) in phosphatase inhibitor-induced apoptosis.
Doctoral dissertation
  • Show author(s) 2018. Preclinical models and molecular biomarkers. Tools to improve treatment in endometrial carcinoma.
  • Show author(s) 2017. Molecular alterations suggesting new treatment strategies in uterine carcinomas.
  • Show author(s) 2016. Hormone signaling related factors as biomarkers in endometrial cancer.
  • Show author(s) 2005. The role of CaMKII and cA-PK in control of cell survival and death.
Academic chapter/article/Conference paper
  • Show author(s) 2013. PI3K Pathway in Gynecologic Malignancies.
  • Show author(s) 2007. Serine/Threonine Protein Phosphatases in Apoptosis. 16 pages.
Abstract
  • Show author(s) 2013. FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 pages.
  • Show author(s) 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
  • Show author(s) 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. 18-18.
Poster
  • Show author(s) 2010. Liver specific transporters of microcystins as a tool to find novel inhibitors of OATP1B1 and OATP1B3.
  • Show author(s) 2003. Myeloid leukemia cell differentiation by bcl-2 and camp involves induction of ccaat/enhancer binding protein ? (c/ebp?), nuclear accumulation of c/ebp?, and direct interaction between bcl-2 and c/ebp?
  • Show author(s) 2002. Effects of a new bioactive substance from a marine microalga on mammalian cells.
  • Show author(s) 2001. TWO NOVEL APOPTOSIS-MODULATION SUBSTANCES ISOLATED FROM MARINE MICRO-ALGAE.
Academic literature review
  • Show author(s) 2020. Improving response to progestin treatment of low-grade endometrial cancer. International Journal of Gynecological Cancer.
  • Show author(s) 2019. Imaging of preclinical endometrial cancer models for monitoring tumor progression and response to targeted therapy. Cancers. 1-16.
  • Show author(s) 2018. Patient-derived xenograft models for endometrial cancer research. International Journal of Molecular Sciences. 1-17.
  • Show author(s) 2018. Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer. International Journal of Molecular Sciences.
  • Show author(s) 2016. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology. 386-401.
  • Show author(s) 2011. The cAMP-dependent protein kinase pathway as therapeutic target - possibilities and pitfalls. Current Topics in Medicinal Chemistry. 1393-1405.
  • Show author(s) 2010. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Molecular Cancer. 135 .

More information in national current research information system (CRIStin)